Compare · CATX vs MDLN
CATX vs MDLN
Side-by-side comparison of Perspective Therapeutics Inc. (CATX) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CATX and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 180.0x CATX ($267.1M).
- Over the past year, CATX is down 51.7% and MDLN is down 11.8% - MDLN leads by 39.9 points.
- MDLN has been more active in the news (7 items in the past 4 weeks vs 5 for CATX).
- MDLN has more recent analyst coverage (25 ratings vs 13 for CATX).
PerformanceCATX-16.22%MDLN-11.77%
2025-12-17+0.00%2026-10-16
- Company
- Perspective Therapeutics Inc.
- Medline Inc.
- Price
- $2.17-7.46%
- $35.95-1.74%
- Market cap
- $267.1M
- $48.08B
- 1M return
- -24.52%
- +11.97%
- 1Y return
- -51.67%
- -11.77%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NASDAQ
- IPO
- 2025
- News (4w)
- 5
- 7
- Recent ratings
- 13
- 25
Latest CATX
- SEC Form 8-K filed by Perspective Therapeutics Inc.
- Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
- Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
- Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
- Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- William Blair initiated coverage on Perspective Therapeutics
- Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
- Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
- Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M